In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on DBV Technologies SA – American, with a price target of $19.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky has given his Buy rating due to a combination of factors related to DBV Technologies’ promising advancements in their peanut allergy treatment programs. The company is nearing a pivotal Phase 3 trial readout for Viaskin Peanut in 4–7-year-olds, with data expected by the end of the year and a potential Biologics License Application submission in the first half of next year. The trial has been designed with improved endpoints and population criteria, which increase the probability of success compared to previous studies.
Furthermore, the peanut allergy market is substantial, with a significant number of young children affected and current treatment options being burdensome. Viaskin Peanut offers a safe, effective, and convenient at-home therapy for ultra-sensitive young patients, which could significantly increase the number of patients seeking treatment. These factors, combined with positive new subset analysis results from previous trials, contribute to the optimistic outlook for Viaskin Peanut’s market potential and DBV Technologies’ stock performance.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 23.0% and a 47.54% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Astria Therapeutics, and Abivax SA Sponsored ADR.